{
    "symbol": "TBPH",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-07 03:16:06",
    "content": " In closing, I'd like to thank GSK for their marketing excellence around TRELEGY, Royalty Pharma for their investment and conviction to move TRELEGY royalty transaction deal forward and invest in ampreloxetine and to the internal Theravance Biopharma team that worked tirelessly to close the deal and meet the needs of the patient communities we serve, the COPD community with YUPELRI's highest sales performance to-date and the MSA community by offering them hope that a more effective and safe option to manage their symptomatic nOH has a path ahead."
}